ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals. (encore1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01011413
Recruitment Status : Completed
First Posted : November 11, 2009
Last Update Posted : December 19, 2014
Sponsor:
Information provided by (Responsible Party):
Kirby Institute

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2013
  Actual Study Completion Date : August 2014

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 February 22, 2018
 
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):